Literature summary extracted from

Patel, V.B.; Clarke, N.; Wang, Z.; Fan, D.; Parajuli, N.; Basu, R.; Putko, B.; Kassiri, Z.; Turner, A.J.; Oudit, G.Y.
Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS (2014), J. Mol. Cell. Cardiol., 66, 167-176.

Activating Compound

EC Number	Activating Compound	Comment	Organism	Structure
3.4.24.86	angiotensin II	treatment with angiotensin II results in angiotensin II type 1 receptor AT1R-mediated increase in myocardial TACE expression and activity, and membrane translocation of TACE	Mus musculus

Organism

EC Number	Organism	UniProt	Comment	Textmining
3.4.24.86	Homo sapiens	P78536	-	-
3.4.24.86	Mus musculus	Q9Z0F8	-	-

Source Tissue

EC Number	Source Tissue	Comment	Organism	Textmining
3.4.24.86	Huh-7 cell	-	Homo sapiens	-

Substrates and Products (Substrate)

EC Number	Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
3.4.24.86	Mca-PLAQAV-Dpa-RSSSR-NH2 + H2O	-	Mus musculus	Mca-PLAQA + V-Dpa-RSSSR-NH2	-	?

Synonyms

EC Number	Synonyms	Comment	Organism
3.4.24.86	TACE	-	Homo sapiens

Expression

EC Number	Organism	Comment	Expression
3.4.24.86	Mus musculus	treatment with angiotensin II results in angiotensin II type 1 receptor AT1R-mediated increase myocardial TACE expression and activity	up

General Information

EC Number	General Information	Comment	Organism
3.4.24.86	physiological function	angiotensin II treatment of Huh-7 cells leads to angiotensin II type 1 receptor-dependent metalloproteinase mediated shedding of ACE2 while transfection with siTACE prevents shedding of ACE2	Homo sapiens
3.4.24.86	physiological function	cardiomyocyte-specific deletion of TACE prevents shedding of ACE2. p47phoxKO mice are resistant to angiotensin II-induced TACE phosphorylation and activation with preservation of myocardial ACE2 which dampens angiotensin II-induced cardiac dysfunction and hypertrophy	Mus musculus

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)